A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2004
11/03/2004	CN1173743C Compositions for treatment of disorders of the oesophagus
11/03/2004	CN1173742C Sustained release medicinal compositions
11/03/2004	CN1173739C Human growth hormone-containing aqueous pharmaceutical composition
11/03/2004	CN1173703C Pharmaceutical composition
11/03/2004	CN1173701C Orally disintegrating composition containing mirtazapine
11/03/2004	CN1173700C Compositions and methods for amelioration of human female sexual dysfunction
11/03/2004	CN1173695C Controlled release and odor masking oral pharmaceutical compositions
11/03/2004	CN1173694C Pharmaceutical composition for treatment of acute disorders
11/02/2004	US6812209 Conjugate consisting of an active substance and a non-exogenous native protein
11/02/2004	US6812204 Delivery of an agent
11/02/2004	US6811996 DDS compounds and method for assaying the same
11/02/2004	CA2364251C Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
11/02/2004	CA2338704C Oral liquid mucoadhesive compositions
11/02/2004	CA2138921C Method of producing a concentrate of anti-d immunoglobulin g and pharmaceutical preparation which contains it
11/02/2004	CA2112014C Antiallergic composition for ophthalmic or nasal use
10/2004
10/30/2004	CA2431742A1 Formulations for anaesthetic use
10/28/2004	WO2004092394A2 Fluid planar lipid layer-based membrane-anchored ligand system with specific binding pair members and methods of use thereof
10/28/2004	WO2004092231A2 Macromolecules auto-assembled and photopolymerised around carbon nanotubes a method for production and application thereof
10/28/2004	WO2004092213A1 Gene expressed in prostate cancer, methods and use thereof
10/28/2004	WO2004092205A1 Hydroxy-substituted-20-acyloxy-camptothecin polymer derivatives and use of the same for the manufacture of a medicament
10/28/2004	WO2004091770A1 Encapsulation system
10/28/2004	WO2004091666A1 Compositions containing piperacillin and tazobactam useful for injection
10/28/2004	WO2004091658A1 High concentration antibody and protein formulations
10/28/2004	WO2004091636A1 Phosphate derivatives of pharmaceutical products
10/28/2004	WO2004091631A1 Androgen pharmaceutical composition and method for treating depression
10/28/2004	WO2004091623A1 Pharmaceutical formulations containing methylnaltrexone
10/28/2004	WO2004091592A2 Methods and compositions to treat myocardial conditions
10/28/2004	WO2004091584A1 Absorption enhancers such as e.g. bht, bha or propyl gallate
10/28/2004	WO2004091583A1 Chrono delivery formulations and method of treating atrial fibrillation
10/28/2004	WO2004091577A1 Composition, method and pharmaceutical preparation for pharmaceutical spray suspensions
10/28/2004	WO2004091553A2 Film forming polymers, methods of use, and devices and applications thereof
10/28/2004	WO2004091551A2 Anti-tumor vasculature effects of human serum albumin derivatives
10/28/2004	WO2004091550A2 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
10/28/2004	WO2004091541A2 Methods for the controlled delivery of pharmacologically active compounds
10/28/2004	WO2004091539A2 Fluid mixing methods and apparatus
10/28/2004	WO2004091538A2 Homogeneous, thermoreversible alginate films and soft capsules made therefrom
10/28/2004	WO2004091537A2 Process for making gel films
10/28/2004	WO2004091536A2 An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
10/28/2004	WO2004091533A2 Delivery systems of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
10/28/2004	WO2004091532A2 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
10/28/2004	WO2004091530A2 Homogeneous, thermoreversible gel film containing kappa-2 carrageenan and soft capsules made therefrom
10/28/2004	WO2004091529A2 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
10/28/2004	WO2004091528A2 Delivery systems of homogeneous thermoreversible alginate films
10/28/2004	WO2004091527A2 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films
10/28/2004	WO2004091500A2 Delivery of immune response modifier compounds
10/28/2004	WO2004091499A2 Intracellular formation of peptide conjugates
10/28/2004	WO2004091498A2 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof
10/28/2004	WO2004091495A2 Compositions and methods related to production of erythropoietin
10/28/2004	WO2004091280A2 Pharmaceutical compositions
10/28/2004	WO2004080490A3 Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
10/28/2004	WO2004073738A3 Composition to be administered to a living being and method for marking agents
10/28/2004	WO2004066925A3 Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same
10/28/2004	WO2004058813A3 Peptides having a high cysteine content
10/28/2004	WO2004053054A3 Nk cell receptor conjugates for treating malignancies
10/28/2004	WO2004042013A3 Identification of diet-regulated disease-associated genes
10/28/2004	WO2004041188A3 Compositions and methods for transdermal oxybutynin therapy
10/28/2004	WO2004022099A3 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
10/28/2004	WO2004016148A3 Shiga toxin b-subunit as a vector for tumor diagnosis and drug delivery to gb3 expressing tumors
10/28/2004	WO2003105908A3 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
10/28/2004	WO2003099991A3 Glp-1 gene delivery for the treatment of type 2 diabetes
10/28/2004	WO2003095522A8 Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders
10/28/2004	WO2003086298A3 Use of interleukin-19 to treat ovarian cancer
10/28/2004	WO2003076490A8 Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
10/28/2004	WO2003064609A3 Targeted immunogens
10/28/2004	WO2003022991A3 Compositions and methods of use of targeting peptides against placenta and adipose tissues
10/28/2004	US20040215292 Photodynamic treatment of targeted cells
10/28/2004	US20040215005 Chitosan preparation
10/28/2004	US20040214996 Multimeric peptides/immunoglobulins for use in the treatment of bone disorders
10/28/2004	US20040214993 Monoclonal antibody for use in prevention and treatment of cell proliferative disorders; immunotherapy; antitumor agents
10/28/2004	US20040214899 aqueous solutions of citric acid, disodium phosphate and (S)-4-{{3-[2-(dimethylaminoethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone, used for prophylaxis of headaches; drug delivery devices; nasal sprays
10/28/2004	US20040214829 Compositions containing alpha-2-adrenergic agonist components
10/28/2004	US20040214797 Preserved pharmaceutical compositions comprising cyclodextrins
10/28/2004	US20040214784 covalent conjugates with mono-, di- , poly- or thiaalkanoic acids; ability to adjust the solubility of steroidal molecules, lipophilicity and bioavailability by altering the structure and length of the acid chain; avoids or reduces the local irritation caused by the parent drug
10/28/2004	US20040214770 Hemoactive compositions and methods for their manufacture and use
10/28/2004	US20040214759 Compositions and methods of use for a fibroblast growth factor
10/28/2004	US20040214753 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
10/28/2004	US20040214752 Dispersible pharmaceutical compositions
10/28/2004	US20040214750 Medicaments for healing skin conditions in humans
10/28/2004	US20040214749 Compositions and methods for treatment of psoriasis
10/28/2004	US20040214748 Hemoglobin conjugates
10/28/2004	US20040214746 Pharmaceutical composition of a tachykinin receptor antagonist
10/28/2004	US20040214328 Multifunctional molecular complexes for gene transfer to cells
10/28/2004	US20040214251 Immunogenic label for detection of low concentrations of viral therapeutics/antibodies in blood; diagnosing/detecion/monitoring viral drug resistance; immunoassay
10/28/2004	US20040214245 Diagnostic and therapeutic use of antibodies against the urokinase receptor
10/28/2004	US20040213881 Taste modifiers comprising a chlorogenic acid
10/28/2004	US20040213855 Pharmaceutical composition for the treatment of acute disorders
10/28/2004	US20040213849 Modified release dosage forms
10/28/2004	US20040213848 Modified release dosage forms
10/28/2004	US20040213845 comprises a drug, polyethylene oxide with a molecular weight of 2,000,000 or higher, and a specific size controlling agent
10/28/2004	US20040213844 one or more active principles solubilised, suspended or embedded in an amphiphilic matrix suitably formulated to modulate the in vitro and in vivo performances of those drugs which require repeated daily administrations or which have to be carried and released at specific sites of gastrointestinal tract
10/28/2004	US20040213840 co-grinding a mixture of drug with a cross-linked polymeric carrier, followed by contacting with water or aqueous vapors causes decrease of insoluble crystalline fraction, increases amorphous fraction, and reduces both nanocrystal fraction and nanocrystals size of drug; increased bioavailabilty
10/28/2004	US20040213839 by maintaining the agent, a flavorant, and a cellulosic material in relatively close physical contact with one another in an oral dosage form
10/28/2004	US20040213836 DRUG DELIVERY; prolonging the time a pharmaceutical drug circulates in the blood of a subject, comprising: introducing into the subject's bloodstream a pharmaceutical composition comprising a liposome containing inventive compound
10/28/2004	US20040213834 Pharmacological preparation made from a nanopatriculate mesomorphous polyelectrolyte lipid complex and at least one active ingredient
10/28/2004	US20040213833 certain MMP inhibitory peptides improve the targeting of liposomes to cancer cells and enhance the uptake thereof by such cells
10/28/2004	US20040213832 non-rate controlled, monolithic, subsaturated patch for transdermal delivery of fentanyl and analogs thereof at a rate and in an amount sufficient to induce and maintain analgesia over a period of at least three days, and up to 7 days to a patient in need thereof
10/28/2004	US20040213804 Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
10/28/2004	US20040213801 targets particular molecules that occur at the cell surface of HIV during viral entry into host cells; humoral response generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells; mechanism of HIV cell entry
10/28/2004	US20040213797 Conjugates for the modulation of immune responses
10/28/2004	US20040213791 Monoclonal antibodies; for diagnosis and treatment of prostate cell proliferative disorders; immunogens; immunotherapy; cell lines

1 ... 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 ... 1712